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Abstract. 
 
Platelet endothelial cell adhesion molecule
(PECAM)-1 is a 130-kD transmembrane glycoprotein
having six Ig homology domains within its extracellular
domain and an immunoreceptor tyrosine–based inhibi-
tory motif within its cytoplasmic domain. Previous stud-
 
ies have shown that addition of bivalent anti–PECAM-1
mAbs to the surface of T cells, natural killer cells, neu-
trophils, or platelets result in increased cell adhesion to
immobilized integrin ligands. However, the mechanism
by which this occurs is not clear, and it is possible that
anti–PECAM-1 mAbs elicit this effect by simply se-
questering PECAM-1, via antibody-induced patching
and capping, away from stimulatory receptors that it
normally regulates. To determine whether dimerization
or oligomerization of PECAM-1 directly initiates signal
transduction pathways that affect integrin function in
an antibody-independent manner, stable human em-
bryonic kidney-293 cell lines were produced that ex-
pressed chimeric PECAM-1 cDNAs containing one or
two FK506-binding protein (FKBP) domains at their
COOH terminus. Controlled dimerization initiated by
addition of the bivalent, membrane-permeable FKBP
dimerizer, AP1510, nearly doubled homophilic binding
capacity, whereas AP1510-induced oligomers favored
cis PECAM-1/PECAM-1 associations within the plane
of the plasma membrane at the expense of trans ho-
mophilic adhesion. Importantly, AP1510-induced oligo-
merization resulted in a marked increase in both adher-
ence and spreading of PECAM/FKBP-2–transfected
cells on immobilized ﬁbronectin, a reaction that was
 
mediated by the integrin 
 
a
 
5
 
b
 
1
 
. These data demonstrate
that signals required for integrin activation can be elic-
ited by clustering of PECAM-1 from inside the cell, and
suggest that a dynamic equilibrium between PECAM-1
monomers, dimers, and oligomers may control cellular
activation signals that inﬂuence the adhesive properties
of vascular cells that express this novel member of the
immunoreceptor tyrosine–based inhibitory motif fam-
ily of regulatory receptors.
Key words: PECAM-1 • integrins • FKBP • dimeriza-
tion • signal transduction
 
Introduction
 
Platelet endothelial cell adhesion molecule (PECAM)
 
1
 
-1 is a
130-kD member of the Ig superfamily and a newly recog-
nized member of the immunoreceptor tyrosine–based inhibi-
tory motif (ITIM) family (Newman et al., 1990; Newman,
1997, 1999). PECAM-1 is expressed on a variety of vascular
and blood cells, including endothelial cells (Newman, 1994),
monocytes, neutrophils (Stockinger et al., 1990), certain sub-
populations of T lymphocytes (Stockinger et al., 1992), and
platelets (Newman, 1994). There is compelling evidence that
PECAM-1 is a multifunctional molecule, as it has been impli-
cated in transendothelial migration of leukocytes (Schim-
menti et al., 1992; Bird et al., 1993; Muller et al., 1993; Vapor-
ciyan et al., 1993; Liao et al., 1995; Christofidou-Solomidou et
al., 1997), T cell activation (Zehnder et al., 1995), and angio-
genesis (DeLisser et al., 1997; Zhou et al., 1999).
Although expressed only diffusely on the surface of indi-
vidual cells, PECAM-1 becomes enriched at sites of cell–
cell contact (Albelda et al., 1991), an effect that appears to
be controlled largely by the extracellular, rather than the
cytoplasmic, domain of the molecule (Sun et al., 2000)
However, during the process of cell migration (Schimmenti
et al., 1992), as well as under certain inflammatory condi-
tions (Ioffreda et al., 1993; Romer et al., 1995), PECAM-1
leaves cell junctions and becomes diffusely localized over
the cell surface. Studies using full-length PECAM-1 incor-
 
Address correspondence to Peter J. Newman, Blood Research Insti-
tute, The Blood Center of Southeastern Wisconsin, P.O. Box 2178, Mil-
waukee, WI 53201. Tel.: (414) 937-6237. Fax: (414) 937-6284. E-mail:
pjnewman@bcsew.edu
 
1
 
Abbreviations used in this paper:
 
 BS
 
3
 
, bis(sulfosuccinikidyl) suberate;
DTSSP, dithiobis(sulfosuccinimidylpropionate); FKBP, FK506-binding
protein; HEK, human embryonic kidney; HEL, human erythroleukemia;
ITIM, immunoreceptor tyrosine–based inhibitory motif; PECAM-1,
platelet endothelial cell adhesion molecule-1. 
The Journal of Cell Biology, Volume 152, 2001 66
 
porated into proteoliposomes and a bivalent PECAM-1/
IgG chimeric protein (PECAM-1/IgG) have shown that
PECAM-1 performs its adhesive function via PECAM-1/
PECAM-1 homophilic interactions, which are mediated
primarily by NH
 
2
 
-terminal Ig homology domains 1 and 2
(Sun et al., 1996a,b; Newton et al., 1997). This region of the
extracellular domain appears to be functionally important,
as mAbs specific for Ig domains 1 or 2 inhibit homophilic
binding (Yan et al., 1995), leukocyte extravasation (Liao et
al., 1995; Nakada et al., 2000), and tumor angiogenesis
(Sheibani et al., 1997; Zhou et al., 1999).
Like many other cell adhesion receptors, PECAM-1 is
able to mediate both outside-in and inside-out signal trans-
duction (Newman, 1997). In particular, there have been
many studies demonstrating that addition of anti–PECAM-1
mAbs to the cell surface results in upregulation of 
 
b
 
1
 
(Tanaka et al., 1992; Leavesley et al., 1994), 
 
b
 
2
 
 (Piali et al.,
1993; Berman and Muller, 1995; Berman et al., 1996), and
 
b
 
3
 
 (Varon et al., 1998; Chiba et al., 1999) integrin function.
Whether these effects are due to PECAM-1–mediated
changes in integrin affinity versus avidity is not well under-
stood, however, Varon et al. (1998) have recently reported
that selected anti–PECAM-1 F(ab
 
9
 
)
 
2
 
 fragments result in
the conformational changes in the integrin 
 
a
 
IIb
 
b
 
3
 
 that aug-
ment platelet adhesion and aggregation. Since monovalent
Fab fragments have been, in general, ineffective integrin
activators, it has been hypothesized that PECAM-1 dimer-
ization or oligomerization may be necessary to transduce
signals into the cell that modulate integrin function.
The mechanism by which antibody-induced dimerization
of PECAM-1 regulates cell surface integrin activation is
not clear, and might simply be due to sequestering PE-
CAM-1, via antibody-induced patching and capping, away
from stimulatory receptors that it normally regulates. To
better understand the potential role of PECAM-1 in inte-
grin activation, we undertook a study designed to examine
(a) whether PECAM-1 might exist in dimeric or oligo-
meric form within the plane of the plasma membrane; (b)
the consequences of such lateral PECAM-1/PECAM-1 as-
sociations on its adhesive and signaling properties; and (c)
the ability of PECAM-1 dimers and oligomers to modulate
integrin function. Using an antibody-independent
 
 
 
ap-
proach that permits precise control of the degree of recep-
tor interactions, we found that PECAM-1 homophilic ad-
hesion is maximally supported by PECAM-1 dimers, but
that integrin activation requires oligomerization of PE-
CAM-1. These data suggest that a dynamic equilibrium be-
tween PECAM-1 monomers, dimers, and oligomers may
control cellular activation signals that influence the adhe-
sive properties of vascular cells that express this novel
member of the ITIM-containing inhibitory receptor family.
 
Materials and Methods
 
Materials
 
PECAM-1.3, a murine anti–human PECAM-1 mAb specific for Ig homol-
ogy domain 1 (Sun et al., 1996b), was fluorescently labeled with Alexa 488
using a protein labeling kit (Molecular Probes). A mouse anti–human
mAb, specific for FKBP-12, MAR4 (mouse anti–human 
 
a
 
5
 
 integrin), and
IIA1 (mouse anti–human 
 
b
 
1
 
 integrin) were purchased from PharMingen.
P1D6 (mouse anti–human 
 
a
 
5
 
 integrin) and P4C10 (mouse anti–human 
 
b
 
1
 
integrin) were purchased from GIBCO BRL. AP1510 and the pCF1E vec-
tor encoding FKBP cDNA were provided by ARIAD Pharmaceuticals,
Inc. (Cambridge, MA). PMSF was purchased from Sigma-Aldrich. Chem-
ical cross-linking agents, bis(sulfosuccinikidyl) suberate (BS
 
3
 
), and dithio-
bis(sulfosuccinimidylpropionate) (DTSSP) were purchased from Pierce
Chemical Co. DTSSP is thiol cleavable, whereas BS
 
3
 
 is noncleavable.
Figure 1. Construction of PECAM-1/FKBP chimeric proteins. (A) Schematic diagram detailing the production of PECAM-1/FKBP-1
and PECAM-1/FKBP-2. cDNAs encoding PECAM-1 and FKBP were used as templates for standard overlap PCR to produce the re-
sulting chimeric proteins, which contain either one or two FKBP dimerization domains. (B) Controlled dimerization and oligomeriza-
tion of PECAM-1. PECAM-1/FKBP-1, containing one FKBP domain, forms self-limiting dimers upon exposure to the cell permeable
synthetic dimerizer AP1510, whereas PECAM-1/FKBP-2 is capable of forming oligomers. 
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Construction of cDNAs Encoding PECAM-1/FKBP-1 
and PECAM-1/FKBP-2 Fusion Proteins 
 
One or two copies of the FK506-binding protein (FKBP), FKBP-12, were
fused, to the COOH terminus of the cytoplasmic domain of PECAM-1,
using standard overlapping PCR techniques (Fig. 1). PECAM-1/FKBP-1,
containing one FKBP motif, was produced by PCR. A segment of PE-
CAM-1 was amplified from amino acid residue 375 to the COOH termi-
nus of PECAM-1 using PECAM-1 primer 1 (5
 
9
 
-CCTGTCAAGTAAG-
GTGGTGGAGTCT-3
 
9
 
) and PECAM-1 primer 2 (5
 
9
 
-CACCTGCA-
CGCCTCTAGAAGTTCCATCAAGGGAGCC-3
 
9
 
), and was joined to a
full-length FKBP motif using FKBP primer 3 (5
 
9
 
-GGCTCCCTTGATG-
GAACTTCTAGAGGCGTGCAGGTG-3
 
9
 
) and FKBP primer 4 (5
 
9
 
-
GTCCTGAATGCTCTTCCAGGCGGCCGCTTATGCGTAGTCTG-
GTAC-3
 
9
 
). The two segments were subsequently mixed together with
primers 1 and 4, and secondary overlap PCR was performed. The final
amplified product was digested with Nhe I and Not I and inserted into
similarly cut wild-type PECAM-1 cDNA that had been cloned into the
mammalian expression vector pcDNA3. PECAM-1/FKBP-2, containing
two FKBP domains fused to the COOH terminus of PECAM-1, was con-
structed by addition of a second FKBP domain to PECAM-1/FKBP-1.
The integrity and authenticity of both constructs were confirmed by nucle-
otide sequencing.
 
Development of Stable PECAM-1/FKBP-1– and 
PECAM-1/FKBP-2–expressing HEK-293 Cell Lines 
 
HEK (human embryonic kidney)-293 cells and human erythroleukemia
(HEL) cells were obtained from American Type Culture Collection and
cultured in MEM and RPMI-1640 medium (Sigma-Aldrich), respectively,
with 10% heat-inactivated fetal calf serum at 37
 
8
 
C in a humidified atmo-
sphere of 5% CO
 
2
 
. HEK-293 cells were grown to 80–90% confluence in
100-mm dishes, incubated with 10 
 
m
 
g of pcDNA3.0 (Invitrogen) contain-
ing PECAM-1/FKBP-1 or PECAM-1/FKBP-2 in a lipofectamine mixture
(GIBCO BRL) for 4 h in serum-free medium (Sigma-Aldrich). Cells were
cultured for an additional 48 h in serum-containing MEM before adding
0.6 mg/ml G418 (geneticin; GIBCO BRL). G418-resistant cell lines were
analyzed, using flow cytometry, for cell surface expression of PECAM-1/
FKBP-1 and PECAM-1/FKBK2. Cell clones were obtained by cell sorting
and limited dilution subcloning. The properties of at least three different
clonal lines were examined so that the influence of clonal variation on the
observed phenotype could be determined.
 
Western Blot and Immunoprecipitation Analysis 
 
HEL and HEK-293 cells were lifted using 0.01% trypsin and 10 mM
EDTA, washed in sterile HPBS, and resuspended at a final concentration
of 10
 
6
 
 cells/ml. Chemical cross-linking was initiated by addition of 2 mM
BS
 
3
 
 or DTSSP for 1 h at 4
 
8
 
C, and then 50 mM Tris-HCl was added to stop
the reaction. Cell lysates were prepared in lysis buffer (2% Triton X-100,
50 mM Tris-HCl, 2 mM PMSF), and the 15,000 
 
g
 
 Triton-soluble fraction
was analyzed under both reducing and nonreducing conditions on a 7%
SDS–polyacrylamide gel. After transfer to an Immobilion-P membrane
(Millipore), proteins were visualized using antibodies to PECAM-1 (PE-
 
CAM-1.3) or FKBP-12 in conjunction with enhanced chemiluminescence
immunodetection (Amersham Pharmacia Biotech) using peroxidase-con-
jugated goat anti–mouse IgG (Jackson ImmunoResearch Laboratories).
For immunoprecipitation analysis, detergent cell lysates were prepared as
above, and the Triton-soluble fractions were incubated with 10 
 
m
 
g/ml PE-
CAM-1.3 IgG overnight at 4
 
8
 
C. Immune complexes were captured with 50
 
m
 
l of 50% slurry of protein G–Sepharose for 1 h at 4
 
8
 
C, and then washed
five times with immunoprecipitation wash buffer (50 mM Tris-HCl, pH
7.4, containing 150 mM NaCl, and 2% Triton X-100). Bound proteins
were eluted from the beads by boiling for 10 min in 30 
 
m
 
l of SDS-reducing
buffer and analyzed by SDS-PAGE, as described above.
 
Flow Cytometry
 
4 
 
m
 
g of PECAM-1.3 or PECAM-1/IgG in 100 
 
m
 
l of HPBS was added to
5 
 
3 
 
10
 
5
 
 wild-type or transfected HEK-293 cells in 100 
 
m
 
l of HPBS and al-
lowed to incubate for 60 min at room temperature in the presence or ab-
sence of various concentrations of AP1510. The cells were then washed by
centrifugation with 1 ml of HPBS and then resuspended in 100 
 
m
 
l of
HPBS containing 1 
 
m
 
g of FITC-labeled goat anti–human or goat anti–
mouse IgG 
 
g
 
 chain (Jackson ImmunoResearch Laboratories). After a 30
min incubation at 4
 
8
 
C, the cells were washed once more in HPBS, and
then subjected to flow cytometric analysis.
 
Fluorescence Microscopy
 
Wild-type or stably transfected 293 cells were incubated in the presence
or absence of 1 
 
m
 
M AP1510 for 30 min at room temperature, and then by
5 
 
m
 
g/ml Alexa 488–conjugated PECAM-1.3 for 30 min at 4
 
8
 
C. The cells
were then washed, fixed with 1% formaldehyde, and mounted onto glass
slides using a cytospin preparation. The cell surface distribution of PE-
CAM-1 was analyzed using a Zeiss fluorescent microscope (ZEISS).
 
Quantitative Evaluation of the Binding of 293 Cells To 
Immobilized Fibronectin 
 
Adherent 293 cells were lifted using 0.01% trypsin and 10 mM EDTA,
washed in sterile HPBS, and resuspended at 10
 
6
 
 cells/ml in prewarmed
(37
 
8
 
C) serum-free medium. After incubation with 2 
 
m
 
g/ml calcein AM
(Molecular Probes) for 30 min at 37
 
8
 
C, cells were washed and resus-
pended at 10
 
6
 
 cells/ml in prewarmed serum-free medium, and then incu-
bated again, this time with varying concentrations of AP1510 in the pres-
ence of selected antibodies for 30 min at 22
 
8
 
C. 200-
 
m
 
l cell aliquots were
then added to wells of 96-well microtiter tissue culture plates (Dynatech
Laboratories) that had been coated with either 10 
 
m
 
g/ml fibronectin
(Sigma-Aldrich) or 10 mg/ml BSA (ICN Biomedicals). Antibody competi-
tion experiments were performed by preincubating cells with varying con-
centrations of selected integrin-specific mAbs for 30 min at 22
 
8
 
C, before
addition of cells to the wells. The reaction was stopped by addition of 70
 
m
 
l of 4% formaldehyde for 15 min at 37
 
8
 
C, and total well fluorescence was
determined in a CytoFluor fluorescent plate reader (PerSeptive Biosys-
tem). Loosely adherent and unbound cells were then removed by washing
the wells with prewarmed serum-free medium, and fluorescence was mea-
sured once more to determine percent cell adhesion.
Figure 2. Chemical cross-linking of cell surface PECAM-1
results in formation of stable high molecular weight
complexes. (A) HEL cells were treated with chemical
cross-linking agents BS3 or DTSSP, and detergent lysates
were analyzed by SDS-PAGE using the anti–PECAM-1
mAb, PECAM-1.3. The prominent 130-kD doublet ob-
served in untreated cells corresponds to variously glyco-
sylated monomeric PECAM-1. Note the high molecular
weight forms corresponding to PECAM-1 dimers and
oligomers. (B) Immunoblot analysis of PECAM-1–trans-
fected HEK-293 lysates that had been exposed to either
BS3 (noncleavable) or DTSSP (cleavable). Note that the
high molecular weight forms of PECAM-1 present under
nonreducing conditions after cross-linking with DTSSP
all revert upon reduction to a single band with a mobility
identical to monomeric PECAM-1, suggesting the pres-
ence of homodimers and homooligomers. 
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Results
 
PECAM-1 Exists in an Equilibrium between 
Monomeric, Dimeric, and Oligomeric Forms Within the 
Plasma Membrane
 
Previous studies have shown that antibody-mediated dimer-
ization or oligomerization of PECAM-1 can lead to upregu-
lation of integrin function in a variety of different cell types.
Whether PECAM-1 actually forms lateral associations within
the plane of the plasma membrane and whether these associ-
ations are able to influence the adhesive phenotype of the
cell are not known. To determine the molecular organization
of PECAM-1 on the cell surface, HEL cells, which constitu-
tively express PECAM-1, and HEK-293 cells, which had
been stably transfected with PECAM-1, were treated with
the homobifunctional 
 
N
 
-hydroxysuccimide–based chemical
cross-linkers BS
 
3
 
 and DTSSP to stabilize preexisting dimers,
oligomers, and other membrane proteins that might be asso-
ciated on the cell surface in close proximity to PECAM-1.
Since PECAM-1 is able to interact homophilically with itself
(Sun et al., 1996a,b), cross-linking reactions were performed
at 4
 
8
 
C at low cell density to minimize trans interactions be-
tween PECAM-1 molecules on adjacent cells.
As shown in Fig. 2, exposure of cells to either BS
 
3
 
 or
DTSSP resulted in the production of stable, high molecu-
lar weight complexes corresponding to dimeric and oligo-
meric forms of PECAM-1. When the high molecular
 
weight complexes formed in the presence of DTSSP were
exposed to reducing conditions, only a 130-kD PECAM-1
doublet remained. Although we cannot exclude the possi-
bility that PECAM-1 is associated with a different 130-kD
protein, these data strongly suggest that the high molecu-
lar weight species are comprised solely of PECAM-1, and
that PECAM-1 is not associated with membrane proteins
other than itself—at least in resting cells.
 
Expression of PECAM-1/FKBP-1 and
PECAM-1/FKBP-2 in HEK-293 Cells 
 
Recent studies have shown that antibody-mediated cross-
linking of PECAM-1 elicits many subsequent downstream
events, including integrin-mediated adhesion (Tanaka et al.,
Figure 3. PECAM-1, PECAM-1/FKBP-1, and PECAM-1/
FKBP-2 expression on 293 cell surface. (A) Flow cytometric
analysis of cell surface expression. Note that untransfected 293
cells do not express PECAM-1, whereas the transfectants express
nearly equivalent level of PECAM-1, PECAM-1/FKBP-1, and
PECAM-1/FKBP-2, respectively. (B) PECAM-1.3 immunoblot
analysis of untransfected 293 cells, or 293 cells transfected with
wild-type PECAM-1, PECAM-1/FKBP-1, and PECAM-1/
FKBP-2. Identical blots were probed with either PECAM-1.3
(left) or anti-FKBP (right). Note that addition of FKBP domains
decreases the mobility of PECAM-1 (left), and also confers im-
munoreactivity to anti-FKBP-12 antibodies (right).
Figure 4. AP1510-induced dimerization and oligomerization of PE-
CAM-1. (A) 293 cells stably expressing PECAM-1/FKBP-2 were
treated with AP1510, and the distribution PECAM-1 visualized with
Alexa 488–conjugated mAb PECAM-1.3. Whereas PECAM-1 oli-
gomers are readily observed, changes in cell surface distribution of
PECAM-1/FKBP-1, upon treatment with AP1510, were not appar-
ent (not shown), probably due to the inability of light microscopy to
visualize simple dimers of the receptor. Bar, 4 mM. (B) 293 cells sta-
bly expressing wild-type PECAM-1, PECAM-1/FKBP-1, and PE-
CAM-1/FKBP-2 were treated with the chemical cross-linking agent
DTSSP in the presence or absence of AP1510, and subjected to im-
munoblot analysis using the anti–PECAM-1 mAb, PECAM-1.3.
Note that nearly all the cell surface PECAM-1/FKBP-1 is forced
into dimers by AP1510, whereas the majority of PECAM-1/FKBP-2
exists in high molecular weight oligomers after AP1510 treatment. 
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1992; Piali et al., 1993; Berman and Muller, 1995; Berman et
al., 1996) and phosphorylation of PECAM-1 itself (Varon et
al., 1998; Newton-Nash and Newman, 1999). However, it is
possible that these effects may have been due, at least in
part, to nonspecific antibody-induced patching and capping.
To examine whether PECAM-1/PECAM-1 associations
within the plane of the membrane can influence cell physiol-
ogy in an antibody-independent manner, we employed an in-
ducible, targeted dimerization and oligomerization system
consisting of PECAM-1/FKBP chimeric proteins and the
synthetic membrane-permeable “dimerizer,” AP1510 (Spen-
cer et al., 1993). As shown in Fig. 3, HEK-293 cell lines trans-
fected with cDNAs encoding wild-type PECAM-1, PE-
CAM-1/FKBP-1, and PECAM-1/FKBP-2 expressed roughly
equivalent levels of the recombinant proteins (Fig. 3 A), and
the chimeric proteins were of the expected size and immu-
noreactivity (Fig. 3 B).
To determine whether AP1510-induced PECAM-1
dimerization or oligomerization could be visualized mor-
phologically, 293-cell transfectants were incubated with
AP1510 and stained with Alexa-conjugated PECAM-1.3.
 
Cells expressing wild-type PECAM-1 showed an even dis-
tribution of PECAM-1 in the presence or absence of
AP1510, as did cells expressing PECAM-1/FKBP-1 (not
shown). However, as shown in Fig. 4 A, oligomerization of
PECAM-1/FKBP-2 by AP1510 could be readily observed.
 
Dimerization and Oligomerization Affect the Adhesive 
Properties of PECAM-1 
 
To determine whether PECAM-1 dimerization or oligo-
merization affects its ability to participate in trans ho-
mophilic interactions, PECAM-1/FKBP-1 and PECAM-1/
FKBP-2 transfectants were incubated with soluble PE-
CAM-1/IgG, a chimeric protein consisting of the extracellu-
lar domain of PECAM-1 fused with the Fc region of human
IgG (Sun et al., 1996b), and binding was quantified by flow
cytometry. As shown in the top graphs of Fig. 5 A, 293 cells
expressing wild-type PECAM-1, PECAM-1/FKBP-1, and
PECAM-1/FKBP-2 bound nearly equivalent amounts of
PECAM-1/IgG in the absence of AP1510, indicating that
the function of the extracellular domain is unaffected by the
presence of FKBP at the COOH terminus. Addition of
AP1510 had no effect on the ability of wild-type PECAM-1
to bind to PECAM-1/IgG, as expected. However, the
AP1510-induced dimerization of PECAM-1/FKBP-1 more
than doubled the binding of PECAM-1/IgG. In contrast,
oligomerization of PECAM-1/FKBP-2 decreased the ho-
mophilic binding capacity by 30–40%. This was not due to
changes in cell surface expression of either PECAM-1 chi-
meric protein, but rather to the inaccessibility of the ho-
mophilic binding site located in Ig domain 1 (data not
shown). As shown in Fig. 5 B, the effect on homophilic
binding of AP1510-induced dimerization was dose depen-
dent, with peak activity occurring at about 1 
 
m
 
M. Together,
these data indicate that cell surface dimers optimally sup-
port high avidity trans homophilic interactions (i.e., cell sur-
face PECAM-1 binding to exogenously added PECAM-1/
IgG, or PECAM-1 on an adjacent cell), whereas PECAM-1
oligomers favor increased cis (i.e., lateral) associations
within the plane of the plasma membrane, at the expense of
decreased trans homophilic binding capacity. A schematic
model consistent with these findings is provided in Fig. 6.
Figure 5. Effect of PECAM-1 dimerization and oligo-
merization on PECAM-1 homophilic adhesion. (A)
PECAM-1/IgG was added to the indicated transfected
293 cell lines in either the absence (top) and presence
(lower) of AP1510. After incubation with FITC-labeled
mouse anti–human Fc, binding was quantified by flow cytometry. At 1 mM, AP1510 more than doubled the amount of PECAM-1/IgG
that became associated with PECAM-1/FKBP-1–transfected cells, an effect that was dose dependent (B) and reversible at high concen-
trations of the drug, probably due to saturation of available FKBP sites and the resulting formation of PECAM-1 dimers and mono-
mers. AP1510 had no effect on PECAM-1/IgG binding to cells expressing wild-type PECAM-1, as expected, however, oligomerization
of PECAM-1/FKBP-2 results in decreased homophilic binding capacity, suggesting that PECAM-1/PECAM-1 cis interactions occur at
the expense of its ability to support trans homophilic interactions.
Figure 6. Model of PECAM-1/IgG binding to monomers,
dimers, and oligomers of PECAM-1 on the cell surface. Note that
the number of PECAM-1/IgG molecules bound is limited by the
availability of free Ig domain 1. The predicted stoichiometry of
PECAM-1/IgG to cell surface PECAM-1 correlates with the flow
cytometric data shown in Fig. 5, i.e., cell surface PECAM-1
dimers maximally support trans homophilic adhesion, whereas
PECAM-1 oligomers are involved in cis interactions. 
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Integrin Activation by Regulated Oligomerization 
of PECAM-1 
 
To determine whether controlled dimerization or oligo-
merization of PECAM-1 from within the cell might be
able to initiate signal transduction pathways that affect in-
tegrin function, 293 cells expressing PECAM-1, PECAM-
1/FKBP-1, and PECAM-1/FKBP-2 were labeled with cal-
cein-AM, and their ability to bind fibronectin-coated mi-
crotiter wells were assessed in the presence or absence of
AP1510. As shown in Fig. 7, adhesion of wild-type– or PE-
CAM-1/FKBP-1–transfected 293 cells to immobilized
fibronectin was unaffected by addition of AP1510. In
contrast, binding and spreading of 293 cells expressing
PECAM-1/FKBP-2 increased markedly upon addition of
AP1510—an effect that was dose dependent (Fig. 7 B).
These data suggest that oligomerization of PECAM-1 is
required for integrin activation, and that PECAM dimer-
ization is insufficient.
Cell adhesion to fibronectin is mediated by many differ-
ent integrins, including 
 
a
 
5
 
b
 
1 
 
(Piotrowicz et al., 1988). To
determine whether the AP1510-induced increase in cell
adhesion was being mediated specifically by this integrin
receptor, we allowed PECAM-1/FKBP-2 cells to adhere to
poly-
 
L
 
-lysine–coated microtiter wells in the presence and
absence of AP1510. As shown in Fig. 8 A, no increase in
cell adhesion to poly-
 
L
 
-lysine was observed upon oligo-
merization of PECAM-1/FKBP-2, suggesting that the
AP1510-induced increase in cell binding to immobilized fi-
bronectin is integrin specific. To determine which integrins
were involved, we examined the effects of integrin sub-
unit–specific inhibitory antibodies on adhesion to fibro-
nectin. Antibodies to 
 
b
 
3
 
, 
 
a
 
2
 
, and 
 
a
 
v
 
 were without effect
(not shown), however mAbs to 
 
a
 
5
 
 and 
 
b
 
1
 
 blocked adhe-
sion to baseline levels (Fig. 8 B), implicating 
 
a
 
5
 
b
 
1
 
 as the in-
tegrin upregulated by PECAM-1 oligomerization in this
system. PECAM-1–mediated adhesion to fibronectin was
not due to increased expression of 
 
a
 
5
 
b
 
1
 
 on the cell surface
(Fig. 8 C), suggesting that the signaling pathway from PE-
CAM-1 to 
 
a
 
5
 
b
 
1
 
 modulated either the affinity or avidity of
this integrin complex.
 
Discussion
 
Like members of the integrin family of adhesion receptors,
there is growing evidence that PECAM-1 is able to partici-
pate in bidirectional signal transduction, i.e., PECAM-1
both initiates and responds to changes in cellular physiol-
ogy. Evidence that engagement of PECAM-1 initiates spe-
cific signal transduction pathways was first provided by
Figure 7. PECAM-1 oligomerization is required to effect integrin activation. (A)
2 3 105 cells in 200 ml of serum-free cell culture media were added to microtiter
wells containing immobilized fibronectin or BSA in the presence or absence of 1
mM AP1510, and cell adhesion was visualized using light microscopy (left) or
quantitated using a fluorescent plate reader (right). Note that oligomerization of
PECAM-1 conferred increased adhesion to fibronectin only for PECAM-1/FKBP-
2–transfected cells. (B) The degree of PECAM-1 oligomerization correlated in a
dose-dependent manner with cell adhesion to fibronectin, with optimal adhesion
occurring at 1 mM AP1510. At higher doses of AP1510, the drug is likely to satu-
rate available FKBP sites, leading to the formation of dimers and monomers. 
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Tanaka et al. (1992). They showed that antibody-induced
dimerization of PECAM-1 on the surface of T cells re-
sulted in their increased adherence to the 
 
b
 
1
 
 integrin sub-
strates VCAM-1 (via 
 
a
 
4
 
b
 
1
 
) and fibronectin (via 
 
a
 
5
 
b1).
Monovalent Fab fragments of PECAM-1 mAbs were inef-
fective, suggesting that dimerization or oligomerization of
PECAM-1 on the cell surface might be responsible for the
observed upregulation of b1 integrin function. Since that
time, affinity modulation of b1 integrins induced by cross-
linking PECAM-1 has been reported in CD341 hemato-
poietic progenitor cells (Leavesley et al., 1994), neutro-
phils (Pellegatta et al., 1998), and eosinophils (Chiba et al.,
1999). Furthermore, b2 integrin function has been shown
to be modulated by PECAM-1 dimerization in lympho-
kine-activated killer cells (Piali et al., 1993), monocytes and
neutrophils (Berman and Muller, 1995), and natural killer
cells (Berman et al., 1996). The ability of PECAM-1 to
function as an integrin activator has recently been ex-
tended to the b3 integrin family by the studies of Varon et
al. (1998). They showed that the binding of anti–PECAM-1
F(ab9)2 fragments caused conformational changes in the
platelet integrin aIIbb3. Chiba et al. (1999) have also shown
that mAb-induced cross-linking of PECAM-1 results in
activation of the endothelial cell avb3, both enhancing ad-
hesion to immobilized RGD peptide and enabling its
heterophilic interaction with leukocyte PECAM-1. Inter-
estingly, these authors found that avb3/PECAM-1 interac-
tions, rather than supporting cell–cell adhesion (as was re-
ported by two other groups [Piali et al., 1995; Buckley et
al., 1996]), instead, constituted an amplification loop that
resulted in PECAM-1–dependent activation of leukocyte
a4b1. Taken together with previous findings, these studies
provide compelling evidence that antibody-induced lateral
associations of PECAM-1 are able to influence integrin
function in a wide variety of vascular cells.
Here, we attempted to address several unresolved ques-
tions related to the ability of PECAM-1 to serve as an
integrin activator. First, we employed a series of hetero-
bifunctional cross-linking agents to determine whether
PECAM-1 might actually exist in other than a monomeric
form on the surface of resting cells. We found evidence for
abundant levels of PECAM-1 cis homodimers and homo-
oligomers (Fig. 2). These findings are consistent with those
of Newton et al. (1999), who found that soluble recombi-
nant forms of PECAM-1 exist in an equilibrium between
monomeric and dimeric states, having a Kd of z12 mM.
Importantly, these investigators also found that PECAM-1
was able to form dimers at 48C on the surface of U937
monocytic cells, as well as PECAM-1–transfected Cos
cells. By using a combination of nonreducible and disul-
fide bond–containing cross-linking reagents, we were able
to examine whether nonPECAM-1 components might
be associated with PECAM-1 complexes, but detected
none—at least in resting cells. Whether cellular activation
results in novel associations of other membrane or cytoso-
lic proteins with PECAM-1 remains an intriguing area for
future investigation.
Previous studies, including our own, on the ability of PE-
CAM-1 to serve as an amplifier of integrin function relied
on the use of bivalent or monovalent mAbs, often in con-
junction with additional bivalent secondary antibodies.
Thus, it has been impossible to determine whether dimer-
ization versus oligomerization of PECAM-1 is sufficient to
effect integrin activation. In addition, these studies all suffer
the limitation that addition of large, bulky antibody mole-
cules to the cell surface can (a) result in antibody-induced
patching, capping, and subsequent “surface-cleansing” and
internalization of antibody–antigen complexes and (b) lead
to nonphysiologic changes in the organization of the under-
lying membrane skeleton and associated signal transduction
machinery. Moreover, many investigations, especially early
on, employed intact antibodies, and the observed “PE-
CAM-1–induced” cellular activation events were undoubt-
edly due to unintentional activation of Fc receptors. Finally,
changes in cellular activation after addition of anti–
PECAM-1 mAbs might be explained by antibody-mediated
Figure 8. PECAM-1 is a specific integrin activator. (A) Calcein AM–
labeled 293 cells expressing PECAM-1/FKBP-2 were added to micro-
titer wells containing immobilized poly-L-lysine or fibronectin in the
presence or absence of AP1510. Note that the increase in cell adhe-
sion induced by oligomerization of PECAM-1 is specific for integrin
substrates, and is mediated by the integrin a5b1, as antibodies to either
of these two integrin subunits reduced cell adhesion to near back-
ground levels (B). The AP1510-induced increase in cell adhesion ap-
pears to operate via either affinity or avidity regulation, as oligomer-
ization of PECAM-1 does not increase the level of cell surface
expression of integrin a5b1 (C).The Journal of Cell Biology, Volume 152, 2001 72
sequestration of this ITIM-containing inhibitory receptor
away from agonist receptors that it normally regulates, re-
sulting in a cell with increased adhesive properties. Such an
explanation has been proposed for the observed stimula-
tory activity of anti-CD22 mAbs, which activate B cells
even though CD22 is now known to be an ITIM-bearing
negative regulator of B cell function (Neel, 1997).
To avoid these potentially artifactual effects, we engi-
neered two different PECAM-1 chimeric proteins express-
ing either one (PECAM-1/FKBP-1) or two (PECAM-1/
FKBP-2) FK506-binding protein domains at their COOH
terminus. When expressed in HEK-293 cells, these PE-
CAM-1 chimeras, in conjunction with the membrane-per-
meable dimerizer AP1510, could be (a) induced to form
controlled, self-limiting dimers or oligomers, respectively,
that remained stably expressed on the cell surface and (b)
examined for their ability to initiate outside-in PECAM-
1–mediated signal transduction. Dimerization of cell sur-
face receptors is commonly used by cells to transmit extra-
cellular signals into the cell interior and regulate cellular
responses (Weiss and Schlessinger, 1998; Remy et al.,
1999), and this FKBP-controlled dimerization system,
originally developed by Spencer et al. (1993), has been
used to imitate Escherichia coli aspartate receptor signal-
ing (Cochran and Kim, 1996), dissect elements of integrin
regulation (Hato et al., 1998), and regulate gene transcrip-
tion (Amara et al., 1997). We found that controlled dimer-
ization of PECAM-1, initiated by addition of AP1510, had
very different effects on the adhesive properties of PE-
CAM-1 compared with oligomerization. Thus, whereas
dimerization nearly doubled homophilic (trans) interac-
tions with soluble PECAM-1, oligomerization of PECAM-1,
instead, increased lateral cis interactions, at the expense
of decreased capacity to support trans homophilic binding
of PECAM-1/IgG (Fig. 5). Physiologically, it is interesting
to note that the basal rate of interaction of leukocytes with
the vessel wall is normally quite low, despite the fact that
monocytes and neutrophils express abundant levels of cell
surface PECAM-1, and that endothelial cells contain up to
106 PECAM-1 molecules/cell, most of which is concen-
trated at cell–cell borders (Newman, 1994). It is possible
that the high concentration of PECAM-1 at endothelial
cell junctions results in lateral cis PECAM-1/PECAM-1
associations that preclude trans homophilic interactions
between PECAM-1 molecules on adjacent cells—a situa-
tion that we appear to have mimicked with AP1510-
induced oligomerization of PECAM-1/FKBP-2. Notably,
upon exposure to tumor necrosis factor-a and g-inter-
feron, PECAM-1 leaves endothelial cell junctions and re-
distributes diffusely onto the cell surface (Romer et al.,
1995). Since leukocyte trafficking occurs under similar in-
flammatory conditions, it is tempting to speculate that the
redistributed cell surface PECAM-1 exists in monomeric
and dimeric form, rather than junctional oligomers, and
that these species may be involved in leukocyte capture
and subsequent transendothelial migration.
A major finding of our present work was the observation
that AP1510-induced oligomerization, but not dimerization,
of PECAM-1 results in a marked increase in both cell adhe-
sion and spreading on immobilized fibronectin (Fig. 7), a re-
action that is (a) mediated by the integrin a5b1 (Fig. 8 B);
(b) not due to changes in the expression level of this cell
surface integrin (Fig. 8 C); and (c) antibody independent,
and, therefore, free of any of the potential artifacts associ-
ated with cellular responses to bound immunoglobulin (dis-
cussed above). Having demonstrated that signals required
for integrin activation can be elicited by clustering of PE-
CAM-1 from within the cell, many important questions re-
main to be addressed. First, we were surprised to find that
whereas PECAM-1 dimers appear to be especially suited to
participate in high affinity trans homophilic interactions,
dimerization of PECAM-1 alone does not appear to be suf-
ficient to effect integrin activation. Might PECAM-1 oligo-
mers uniquely associate with other, still-to-be-identified
molecules within the plane of the plasma membrane, or
with cytosolic signaling molecules or cytoskeletal compo-
nents, to exert their effects? Second, whereas PECAM-1
monomers, dimers, and oligomers exist in equilibrium on
the cell surface (Fig. 2), the cell physiological processes that
control the dimerization/oligomerization state of PECAM-1
have not yet begun to be examined, and the regions within
PECAM-1 that mediate lateral cis associations remain to be
identified. Finally, whereas selected members of the b1, b2,
and b3 integrin family have been shown to be capable of PE-
CAM-1–mediated activation, the full range of integrins
whose function can be modulated by PECAM-1 remains to
be determined. Answers to these and related questions are
the subject of active, ongoing investigations in various labo-
ratories, and should provide significant insight into the abil-
ity of this molecule to influence the adhesive phenotype of
the vascular cells that express it.
In summary, the production of PECAM-1/FKBP chi-
meric proteins, in conjunction with the use of the mem-
brane-permeable dimerizer, AP1510, has allowed us to de-
termine specific functional consequences of PECAM-1
homodimerization and oligomerization. We found that
PECAM-1 dimers, but not oligomers, efficiently support
trans PECAM-1 homophilic interactions, and provided a
model that predicts that such species, when present on the
surface of adjacent cells that contact each other, may facil-
itate cellular interactions that lead to leukocyte transen-
dothelial migration. In contrast, the ability of PECAM-1
to serve as a positive modulator of integrin function re-
quires supermolecular associations within the plane of the
plasma membrane. Taken together, these data suggest that
a dynamic equilibrium between PECAM-1 monomers,
dimers, and oligomers may control cellular activation sig-
nals that influence the adhesive properties of vascular cells
that express this novel member of the ITIM-containing in-
hibitory receptor family. Further studies aimed at charac-
terizing the components of the bidirectional signaling
pathway that enable communication between integrins
and PECAM-1 are likely to improve our understanding of
the role of PECAM-1 in inflammation, angiogenesis, and
the immune response.
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